Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Drugs Made In America Acquisition Corp. ( (DMAA) ) is now available.
Drugs Made In America Acquisition Corp., a SPAC affiliated with Drugs Made In America Acquisition II Corp., operates by holding investor capital in a segregated trust account while it seeks a business combination. The affiliate completed its IPO on September 26, 2025, establishing a working capital account and a separate trust structure for investor protections.
The company disclosed that, between September 26, 2025, and December 31, 2025, the sponsor of its affiliate made improper withdrawals from the affiliate’s working capital account, prompting an immediate review of the parent company’s own funds. Following this review, the board confirmed on March 6, 2026, that the irregularities did not affect its trust account and that approximately $241,292,436 remained intact, reassuring stakeholders about the security of core IPO proceeds.
More about Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. is a special purpose acquisition company focused on completing a business combination, primarily operating through a trust account that holds funds raised in its initial public offering. The company is affiliated with Drugs Made In America Acquisition II Corp., which completed its own IPO on September 26, 2025.
Average Trading Volume: 44,790
Technical Sentiment Signal: Strong Buy
Current Market Cap: $351.6M
See more data about DMAA stock on TipRanks’ Stock Analysis page.